TWI464161B - 醛去氫酶活性之調節劑及其使用方法 - Google Patents

醛去氫酶活性之調節劑及其使用方法 Download PDF

Info

Publication number
TWI464161B
TWI464161B TW098130086A TW98130086A TWI464161B TW I464161 B TWI464161 B TW I464161B TW 098130086 A TW098130086 A TW 098130086A TW 98130086 A TW98130086 A TW 98130086A TW I464161 B TWI464161 B TW I464161B
Authority
TW
Taiwan
Prior art keywords
group
subject
substituted
aldehyde dehydrogenase
alkyl
Prior art date
Application number
TW098130086A
Other languages
English (en)
Chinese (zh)
Other versions
TW201022250A (en
Inventor
Wenjin Yang
Che-Hong Chen
Daria Mochly-Rosen
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of TW201022250A publication Critical patent/TW201022250A/zh
Application granted granted Critical
Publication of TWI464161B publication Critical patent/TWI464161B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW098130086A 2008-09-08 2009-09-07 醛去氫酶活性之調節劑及其使用方法 TWI464161B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9522708P 2008-09-08 2008-09-08

Publications (2)

Publication Number Publication Date
TW201022250A TW201022250A (en) 2010-06-16
TWI464161B true TWI464161B (zh) 2014-12-11

Family

ID=41797485

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098130086A TWI464161B (zh) 2008-09-08 2009-09-07 醛去氫酶活性之調節劑及其使用方法

Country Status (7)

Country Link
US (3) US8354435B2 (enExample)
EP (1) EP2337563B1 (enExample)
JP (2) JP2012502048A (enExample)
CN (1) CN102209541B (enExample)
ES (1) ES2477552T3 (enExample)
TW (1) TWI464161B (enExample)
WO (1) WO2010028175A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
CA2839703A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
KR20150135332A (ko) * 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物
FR3054564B1 (fr) 2016-07-28 2018-08-31 Advanced Biodesign Substrat specifique d'une isoenzyme de l'aldh
CN117105868A (zh) * 2022-05-24 2023-11-24 中国人民解放军海军军医大学 酰胺类醛脱氢酶激动剂、其合成方法及用途
CN115160285B (zh) * 2022-08-25 2022-11-29 云南大学 硫代酰胺类aldh2激动剂、制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053544A1 (en) * 2000-12-29 2002-07-11 Darwin Discovery Ltd. Pharmaceutical uses and synthesis of nicotinanilide-n-oxides
US6939882B1 (en) * 1999-08-18 2005-09-06 Aventis Cropsciences Gmbh Fungicides

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2319808A (en) 1939-08-31 1943-05-25 Squibb & Sons Inc Sterol derivatives and process for producing same
DE2417763A1 (de) 1974-04-11 1975-10-30 Bayer Ag Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US4992418A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
JPH01203351A (ja) 1988-02-05 1989-08-16 Mitsui Petrochem Ind Ltd 1,4−ジヒドロキシナフタレン誘導体および医薬
JPH023351A (ja) 1988-06-16 1990-01-08 Oki Electric Ind Co Ltd 印刷装置
US4861891A (en) 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
JPH03184973A (ja) 1989-12-14 1991-08-12 Rooman Kogyo:Kk 放射線障害防護剤
US5260323A (en) * 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
DE4201047A1 (de) 1992-01-17 1993-07-22 Bayer Ag Substituierte isoxazolcarbonsaeureamide
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
JP2994182B2 (ja) 1992-07-23 1999-12-27 石原産業株式会社 アミド系化合物又はその塩、それらの製造方法及びそれらを含有する有害動物防除剤
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
JP3833281B2 (ja) * 1995-02-03 2006-10-11 日本曹達株式会社 2,6−ジクロロイソニコチン酸ベンジルアミド誘導体及び植物病害防除剤
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
PT1019385E (pt) 1995-09-15 2004-06-30 Upjohn Co N-oxidos de aminoaril-oxazolidinona
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
CN1327443A (zh) * 1997-10-31 2001-12-19 艾文蒂斯药品有限公司 取代的酰苯胺化合物
WO1999032444A1 (en) 1997-12-22 1999-07-01 Eli Lilly And Company Catalyst and method for amide formation
EP1080069B1 (en) 1998-04-20 2003-03-19 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
US6780883B2 (en) * 1998-11-05 2004-08-24 Warner-Lambert Company Amide inhibitors of microsomal triglyceride transfer protein
AU775388B2 (en) 1998-11-25 2004-07-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scavenger compounds
WO2001032928A2 (en) 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
EP1402026A2 (en) 2000-04-18 2004-03-31 Millennium Pharmaceuticals, Inc. 39228, a human alcohol dehydrogenase and uses therefor
EP1351946A2 (en) 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
NZ524421A (en) * 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
DE60137944D1 (de) * 2000-09-15 2009-04-23 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6678516B2 (en) 2001-05-21 2004-01-13 Nokia Corporation Method, system, and apparatus for providing services in a privacy enabled mobile and Ubicom environment
EP1402890B1 (en) 2001-06-08 2008-01-09 Institute of Medicinal Molecular Design, Inc. Sulfonamide derivatives
US20050009812A1 (en) 2001-10-05 2005-01-13 Takuya Seko Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
CN1625549A (zh) 2002-01-31 2005-06-08 辉瑞产品公司 (3-{[4-叔丁基-苄基)-(吡啶-3-磺酰基)-氨基]-甲基}-苯氧基)-乙酸的代谢物
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
US7598418B2 (en) 2002-04-18 2009-10-06 Institute Of Medicinal Molecular Design, Inc. Amide derivatives
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
MXPA05002508A (es) * 2002-09-06 2005-06-03 Elan Pharm Inc Derivados de profarmaco 1,3-diamino-2-hidroxipropano.
EP1402887A1 (en) 2002-09-18 2004-03-31 Jerini AG New compounds for the inhibition of undesired cell proliferation and use thereof
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP4359754B2 (ja) * 2003-07-03 2009-11-04 三菱瓦斯化学株式会社 基板の洗浄剤
WO2005007889A1 (en) 2003-07-21 2005-01-27 Oncotherapy Science, Inc. Method for diagnosing colorectal cancers
WO2005011561A2 (en) 2003-08-04 2005-02-10 Labcoat, Ltd. Stent coating apparatus and method
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
EP1661572A1 (en) 2003-08-18 2006-05-31 Shionogi & Co., Ltd. Novel use of cannabinoid receptor agonist
FR2861071B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861074B1 (fr) 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2007518401A (ja) 2003-12-09 2007-07-12 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−2を調節するための方法および組成物
GT200500013A (es) * 2004-01-23 2005-08-10 Amidas herbicidas
US20080021083A1 (en) 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
JP2007538024A (ja) 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
CN1749415A (zh) 2004-09-15 2006-03-22 上海人类基因组研究中心 硝酸甘油治疗急性心绞痛疗效检测方法和试剂盒
US7456194B2 (en) * 2004-11-12 2008-11-25 Bristol-Myers Squibb Company Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7888374B2 (en) * 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
EP1937639B1 (en) 2005-09-23 2010-03-03 Pfizer Products Incorporated Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
CA2631777A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
EP2001851A2 (en) * 2006-03-28 2008-12-17 Novartis AG Amide derivatives and their application for the treament of g protein related diseases
WO2007132841A1 (ja) * 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
US9012419B2 (en) 2006-05-17 2015-04-21 University Of Utah Research Foundation Methods and compositions related to eosinophil regulation
US20080003585A1 (en) 2006-06-29 2008-01-03 Bio-Rad Laboratories, Inc., A Corporation Of The State Of Delaware Purification and amplification of nucleic acids in a microfluidic device
WO2008014497A2 (en) 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
CA2661503A1 (en) 2006-08-25 2008-02-28 Vitae Pharmaceuticals, Inc. Inhibitors of 11.beta. -hydroxysteroid dehydrogenase type 1
EP1932834B1 (en) * 2006-12-11 2011-04-27 The Genetics Company, Inc. Aromatic 1,4-DI-Carboxylamides and their use
JP5178738B2 (ja) * 2006-12-20 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 新規なjnk阻害剤
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
WO2008103354A2 (en) 2007-02-20 2008-08-28 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009137045A2 (en) 2008-05-07 2009-11-12 The Board Of Trustees Of The Leland Stanford Junior University Crystal structure of aldehyde dehydrogenase and methods of use thereof
US8742123B2 (en) 2008-06-04 2014-06-03 Taimed Biologics, Inc. HIV integrase inhibitors from pyridoxine
PE20110136A1 (es) * 2008-06-27 2011-03-17 Novartis Ag Compuestos organicos
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
US8552200B2 (en) 2010-10-20 2013-10-08 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
EP2651412A4 (en) 2010-12-14 2014-08-13 Beth Israel Hospital ANDROGEN RECEPTOR AND HER APPLICATION PROCEDURES
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939882B1 (en) * 1999-08-18 2005-09-06 Aventis Cropsciences Gmbh Fungicides
WO2002053544A1 (en) * 2000-12-29 2002-07-11 Darwin Discovery Ltd. Pharmaceutical uses and synthesis of nicotinanilide-n-oxides

Also Published As

Publication number Publication date
WO2010028175A1 (en) 2010-03-11
JP2015051983A (ja) 2015-03-19
EP2337563A4 (en) 2012-09-12
US20100063100A1 (en) 2010-03-11
ES2477552T3 (es) 2014-07-17
TW201022250A (en) 2010-06-16
US8354435B2 (en) 2013-01-15
JP2012502048A (ja) 2012-01-26
US8906942B2 (en) 2014-12-09
US20130253010A1 (en) 2013-09-26
CN102209541B (zh) 2016-05-18
CN102209541A (zh) 2011-10-05
EP2337563A1 (en) 2011-06-29
US9345693B2 (en) 2016-05-24
EP2337563B1 (en) 2014-04-09
US20150182511A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
TWI464161B (zh) 醛去氫酶活性之調節劑及其使用方法
TWI486349B (zh) 醛脫氫酶調節劑及其用法
Hammock et al. Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative
ES2261202T3 (es) Derivados de acido de triarilo como ligandos para el receptor ppar.
JP2003525217A (ja) 肥満治療用薬剤
KR20090117950A (ko) 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법
TW200837055A (en) Soluble epoxide hydrolase inhibitors
US20130158028A1 (en) Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
CA2736441A1 (en) Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
US20150045387A1 (en) Bi-Aromatic And Tri-Aromatic Compounds As NADPH Oxidase 2 (Nox2) Inhibitors
AU775591B2 (en) Anxiety method
CA2512563C (en) Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
Lorthioir et al. Diabetic CVD–soluble epoxide hydrolase as a target
TW202019486A (zh) 用於治療腎臟病之化合物
US20140212486A1 (en) Isometheptene isomer
JPS60500288A (ja) 3−(3−置換アミノ−2−ヒドロキシプロポキシ)−4−置換−1・2・5−チアゾ−ル誘導体のエステル
TW200930359A (en) Soluble epoxide hydrolase inhibitors
Aiello et al. Tryptophan hydroxylase 1 (TPH1) Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees